JP2008195618A - Peptide composition for inducing oral immune tolerance and method for producing the same - Google Patents

Abstract

Disclosed is a substance capable of removing T cell reactivity, having T cell reactivity capable of inducing immune tolerance for a long time with a small amount of antigen, and capable of being used for the treatment and prevention of milk allergy in humans.
A peptide composition having a specific amino acid sequence obtained by treating a protein derived from milk with a protein hydrolase has a low B cell reactivity and is important for inducing immune tolerance. Has cell reactivity.
[Selection figure] None

Description

  The present invention relates to a peptide composition that effectively induces oral immune tolerance and a method for producing the same. Furthermore, it relates to an oral tolerance inducer comprising this peptide composition as an active ingredient. The peptide composition of the present invention has a specific amino acid sequence, and can induce oral immune tolerance useful for the treatment and prevention of milk allergy and the like.

  In general, a living body shows an immune response against a heterologous (non-self) antigen, but does not show an immune response against an antigen constituting the self. On the other hand, even a heterologous antigen may not show an immune response, which is called immune tolerance. In particular, it is known that the responsiveness of an antigen taken orally and absorbed into the body via the intestinal tract is significantly reduced, and this is called oral tolerance. The mechanism of action of this oral tolerance is thought to be through three regulatory mechanisms: clonal anergy, clonal deletion, and active suppression. Clonal anergy means that immune cells become unresponsive to an antigen, and it has been shown that lymphocytes that enter an anergy state are CD4 + T cells (see Non-Patent Document 1). Further, clonal deletion is a phenomenon in which T cells that react with an antigen undergo apoptosis and disappear. Active suppression is known to play a major role in regulatory T cells that produce IL-10, an anti-inflammatory cytokine (see Non-Patent Document 2). As described above, since oral immune tolerance is established by a control mechanism centered on T cells, a healthy person does not elicit an immune reaction that is detrimental to the living body even when milk is ingested. However, in patients with milk allergies, oral tolerance is not established, and after milk is ingested, it is absorbed from the intestinal tract and milk protein binds to IgE released from B cells, and crosslinks and binds on mast cells. Thereafter, chemical mediators such as IL-4 are released from the mast cells, and allergic symptoms such as urticaria and anaphylactic shock are excited and may result in death.

  Thus, attempts have been made to prevent or treat milk allergy by inducing oral immune tolerance, and those using protein hydrolysates for preventing the onset of milk allergy have been disclosed (Patent Documents 1 and 2). reference). In addition, attempts have been made to modify the responsiveness of immune cells by modifying milk protein with drugs (see Non-Patent Document 3).

  However, there are several problems with inducing oral tolerance. First, since many subjects who induce oral tolerance are milk allergic patients, if the B cell reactivity that triggers allergies remains as described above, it can cause serious symptoms such as anaphylactic shock and die. Sometimes. Therefore, it is desirable that B cell reactivity has disappeared or has been reduced. Furthermore, when a drug or a chemically synthesized peptide is used in inducing oral immune tolerance in human subjects, there are drawbacks in that it has a safety problem and becomes very expensive.

  Next, as reported in Patent Document 1, in which oral tolerance is induced, experiments are usually conducted using mice. However, it is said that there is a difference in the ease of induction of oral immune tolerance depending on the type of animal, and rodents such as mice and rats are particularly likely to be induced. In particular, as described above, T cells play a very important role in the establishment of oral tolerance, but it has been reported that the site recognized by T cells varies depending on the mouse strain (non-patent literature). 4 and 5). Therefore, even if oral tolerance is induced in mice, it is not necessarily induced in humans. Therefore, it cannot be said that oral tolerance is induced unless T cell reactivity in humans is demonstrated. Moreover, in the prior art, a method for preparing a highly effective peptide is insufficient, and in Patent Document 1, the molecular weight to be fractionated is as high as 10,000, and the B cell reactivity is also high. Furthermore, Patent Document 2 does not discuss any confirmation of a specific amino acid sequence having T cell reactivity.

Therefore, it has been desired to develop a peptide that can reduce B cell reactivity as much as possible, while having T cell reactivity, and more efficiently induce oral tolerance to humans.
JP-A-5-5000 Japanese Unexamined Patent Publication No. 7-101873 Hirahara, K. et al., J. Immunol., (1995) Hiroshi Seino: History of Medicine (2002) Kobayashi, K. et al., Bioconjug. Chem., (2003) Tsuji, NM et al., Immunol. Lett., (1993) Totsuka, M. et al., Cytotechnology, (1997)

  The present invention eliminates B cell reactivity that causes severe symptoms such as anaphylactic shock via IgE, has T cell reactivity that can induce immune tolerance for a long time with a small amount of antigen, milk allergy in humans, etc. It is an object of the present invention to establish and provide a peptide composition that can be used for the treatment / prevention of cancer and a preparation method thereof.

  In order to solve the above problems, first, the allergenicity of proteins contained in milk was compared. As a result, although various proteins such as α, β, κ, γ-casein, α-lactalbumin and β-lactoglobulin are present in milk, β-lactoglobulin has the highest antigenicity, and milk It became clear that the allergic patients also had high reactivity. Therefore, a synthetic peptide that covers the entire amino acid sequence of β-lactoglobulin, which is a major allergen in milk, was prepared, and human T cell epitopes were identified. As a result, sequences up to 97-117 of all β-lactoglobulin amino acid sequences (Thr-Asp-Tyr-Lys-Lys-Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala -Glu-Pro-Glu-Gln-Ser-Leu (hereinafter referred to as peptide 2) was identified as the major human T cell epitope. Based on this information, we have eagerly studied the degradation of protein derived from milk with protein hydrolase and the fractionation method with ultrafiltration membranes, which are important for low B cell reactivity and induction of immune tolerance. We have succeeded in developing a peptide with high T cell reactivity.

In order to obtain the peptide of the present invention, a protein derived from milk is used as a substrate, a protein hydrolase is added thereto, and hydrolysis is performed at a predetermined pH and temperature for a necessary time.
For example, an endo-type enzyme is added to a β-lactoglobulin WPC aqueous solution, and the substrate concentration is 0.5 to 15%, the pH is 7 to 8, the temperature is 40 to 50 ° C., and the treatment is performed for 1 hour to 6 hours. Furthermore, it is desirable to purify using an ultrafiltration membrane having an average molecular weight cut off of 10,000, 5,000 or 1,000 in order to remove a higher antigenic polymer substance. For ultrafiltration membranes, the molecular weight size that can be fractionated may differ from the displayed molecular weight size depending on the membrane material and conditions, so combine ultrafiltration membranes with different average molecular weights and different molecular weight sizes. Can also be used. Furthermore, it is more desirable that the peptides in the composition are fractionated to a molecular weight of 1,000 or more and 5,000 or less using a combination of these ultrafiltration membranes.

The peptide thus obtained showed the same level of reactivity as the 97-117th synthetic peptide (peptide 2) described above in T cells of milk allergy patients, so that the T cell epitope remaining in the composition remained. As a result of comprehensive analysis from the point of view, the sequence from the 102nd to the 124th in the total β-lactoglobulin 162 amino acid sequence (Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala-
All and / or part of Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu-Val-Arg [Formula 2]; All of the amino acid sequences (Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu [Formula 3]; hereinafter referred to as Peptide 4) and Peptides containing / or part were identified.
Therefore, from the result of the synthetic peptide and the peptide composition obtained this time, the 97th to 124th sequence (Thr-Asp-Tyr-Lys-Lys-Tyr-Leu-Leu-Leu-Phe in the total 162 amino acid sequences of β-lactoglobulin) -Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu-Val-Arg [Formula 1]; It has been shown that it may be important to include and / or part of it.

It has been pointed out that one of the causes of food allergies found in infants is that a part of food protein is absorbed from the intestine without being degraded by digestive enzymes and stimulates the biological immune system. In this regard, since the peptide composition of the present invention has a very low average molecular weight, the antigenicity of the original undegraded milk protein is greatly reduced and can be used for the treatment of milk allergy patients. . On the other hand, since this peptide composition is very high in terms of the ability to induce oral tolerance, it can sufficiently activate the potential allergy defense mechanism of the living body.
Therefore, the peptide composition of the present invention is useful as a food material or oral tolerance tolerance inducer for the purpose of reducing allergy, preventing and treating new allergies.

  A milk protein is used as a raw material of the peptide according to the present invention. In particular, a whey protein concentrate (Whey protein concentrate: WPC) or a whey protein isolate (WPI) containing a high content of β-lactoglobulin is used. Furthermore, it is desirable that these proteins have higher purity.

In the present invention, the aforementioned milk-derived protein is treated with a protein hydrolase to form a low molecular peptide.
Protein hydrolase broadly refers to enzymes that hydrolyze peptide bonds and includes proteases, proteinases, endopeptidases, etc., and there are plant-derived, animal-derived, and microorganism-derived enzymes. The enzymes used in the present invention are preferably endo-type enzymes, particularly trypsin, chymotrypsin and alkaline protease.

In practicing the present invention, a protein derived from milk is used as a substrate and a protein hydrolase is added thereto, followed by hydrolysis at a predetermined pH and temperature for a necessary time.
For example, an endo-type enzyme is added to a β-lactoglobulin WPC aqueous solution and treated at a substrate concentration of 0.5 to 15%, pH of 7 to 8, a temperature of 40 to 50 ° C., and a range of 1 to 6 hours. Furthermore, it is desirable to purify using an ultrafiltration membrane having a molecular weight of 10,000, 5,000 or 1,000 in order to remove a higher antigenic polymer substance. For ultrafiltration membranes, the molecular weight size that can be fractionated may differ from the displayed molecular weight size depending on the membrane material and conditions, so combine ultrafiltration membranes with different average molecular weights and different molecular weight sizes. Can also be used. Furthermore, it is more desirable that the peptides in the composition are fractionated to a molecular weight of 1,000 or more and 5,000 or less using a combination of these ultrafiltration membranes.

  The peptides thus obtained showed the same level of reactivity as the 97-117th synthetic peptide (Peptide 2) described above in T cells of milk allergy patients. As a result of analysis, a peptide containing all and / or part of the sequence up to positions 102 to 124 ([Formula 2]; Peptide 3) out of all 162 amino acid sequences of β-lactoglobulin was identified. Therefore, from the result of the synthetic peptide and the peptide composition obtained this time, all and / or part of the 97th to 124th sequence ([Formula 1]; Peptide 1) in the entire 162 amino acid sequence of β-lactoglobulin is included. It was suggested that things were important.

  Based on the above results, this enzyme-degraded peptide composition has low antigenicity due to reduced B cell reactivity, and has the same ability to induce immune tolerance as an undegraded milk-derived protein. Because of its excellent processing characteristics such as heat resistance, it can be used as a new allergy prevention / treatment food material, alone or various beverages such as soft drinks, mineral water and tea, and confectionery such as cookies, biscuits and rice crackers. Or, it can be used freely with foods such as infant formula, bread, jelly, and oral refreshing confectionery.

  In addition, since the enzymatically degradable peptide composition according to the present invention has human T cell reactivity and is excellent in oral immune tolerance inducing ability as will be described later, tablets, granules, capsules, powders, solutions It can be formulated into a desired dosage form and used as an oral administration agent to induce oral tolerance and / or as an auxiliary treatment therefor. Since the degraded peptide composition according to the present invention can be used as a food originally, there is no problem in safety, and the dose may be appropriate.

  Examples and test examples are shown below, and the present invention is further described in detail.

Synthetic peptides having various sequences were prepared so as to cover the entire sequence of β-lactoglobulin (hereinafter abbreviated as BLG). About the obtained synthetic peptide, cell proliferation property was evaluated using the T cell clone established from the serum of a milk allergy patient. As a result, the amino acid sequence corresponding to positions 97-117 of the BLG amino acid sequence Thr-Asp-Tyr-Lys-Lys-Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro -Glu-Gln-Ser-Leu (peptide 2) peptide showed T cell reactivity (Figure 1).
In order to obtain a peptide composition containing two peptide fractions, 5 g of BLG-WPC (protein content 80%, Domo) was dissolved in 1000 ml of ion-exchanged water to a substrate concentration of 0.5%. After adjusting to pH 8 with sodium hydroxide, 100 mg of purified trypsin (derived from porcine pancreas, trypsin activity of 4,500 USP / mg or more, chymotrypsin activity of 50 USP / mg or less) was added to an enzyme / substrate ratio of 2.0%, 40 ° C, 6 ° C The enzyme reaction was performed for a time. After completion of the reaction, the mixture was boiled at 100 ° C. for 10 minutes to deactivate the enzyme activity to obtain an enzyme-decomposed peptide composition. In the peptide composition, the amino acid sequence corresponding to positions 102 to 124 of all 162 amino acid sequences of β-lactoglobulin is Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro- A peptide of Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu-Val-Arg ([Formula 2]; Peptide 3) was confirmed.

  5 g of BLG-WPC (protein content 80%, Domo) was dissolved in 1000 ml of ion-exchanged water to obtain a substrate concentration of 0.5%. Adjust pH to 8 with sodium hydroxide, add 100 mg trypsin (derived from porcine pancreas, trypsin activity 1,200 units / mg or more, chymotrypsin activity 300 units / mg or less) to 2.0% enzyme / substrate ratio, 40 ° C., 6 hours The enzyme reaction was performed. After completion of the reaction, the mixture was boiled at 100 ° C. for 10 minutes to deactivate the enzyme activity to obtain an enzyme-decomposed peptide composition. In the peptide composition, the amino acid sequence Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu- A peptide of Val-Cys-Gln-Cys-Leu ([Formula 3]; Peptide 4) was confirmed.

  5 g of BLG-WPC (protein content 80%, Domo) was dissolved in 1000 ml of ion-exchanged water to obtain a substrate concentration of 0.5%. After adjusting to pH 8 with sodium hydroxide, 100 mg of trypsin (derived from porcine pancreas, trypsin activity 1,200 units / mg or more, chymotrypsin activity 300 units / mg or less) was added to 2.0% of the enzyme / substrate ratio, 40 ° C., 6 hours, Enzymatic reaction was performed. After completion of the reaction, the mixture was boiled at 100 ° C. for 10 minutes to deactivate the enzyme activity to obtain an enzyme-decomposed peptide composition. Fractions were obtained by fractionation with an ultrafiltration membrane having an average molecular weight cut off of 10,000. Further, the permeate was fractionated with an ultrafiltration membrane having an average molecular weight cut off of 1,000 to obtain a retentate. In the peptide composition, the 97-124th sequence (Thr-Asp-Tyr-Lys-Lys-Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn- Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu-Val-Arg [Formula 1]; peptide containing all and / or part of peptide 1) is confirmed It was.

  5 g of BLG-WPI (protein content 87%, Davisco) was dissolved in 100 ml of ion-exchanged water to give a substrate concentration of 5.0%. After adjusting to pH 8 with sodium hydroxide, 100 mg of purified trypsin (derived from porcine pancreas, trypsin activity of 4,500 USP / mg or more, chymotrypsin activity of 50 USP / mg or less) was added to an enzyme / substrate ratio of 2.0%, 40 ° C, 6 ° C The enzyme reaction was performed for a time. After completion of the reaction, the mixture was boiled at 100 ° C. for 10 minutes to deactivate the enzyme activity to obtain an enzyme-decomposed peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average molecular weight cut off of 5,000 to obtain a permeate. In the peptide composition, a peptide containing all and / or part of the 97th to 124th sequence ([Formula 1]; Peptide 1) in the entire 162 amino acid sequence of β-lactoglobulin was confirmed.

  75 g of BLG-WPI (protein content 87%, Davisco) was dissolved in 500 ml of ion-exchanged water to give a substrate concentration of 15.0%. After adjusting to pH 7 with 50 mM phosphate buffer, 150 mg of purified trypsin (derived from porcine pancreas, trypsin activity of 4,500 USP / mg or more, chymotrypsin activity of 50 USP / mg or less) is added to an enzyme substrate ratio of 0.2%, 50 ° C., 1 The enzyme reaction was performed for a time. After completion of the reaction, the mixture was boiled at 100 ° C. for 10 minutes to deactivate the enzyme activity to obtain an enzyme-decomposed peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average fractional molecular weight of 10,000 to obtain a permeate. Further, the permeate was fractionated with an ultrafiltration membrane having an average molecular weight cut off of 1,000 to obtain a retentate. In the peptide composition, a peptide ([Formula 1]; Peptide 1) containing all and / or a part of the 97th to 124th sequence in the entire β-lactoglobulin 162 amino acid sequence was confirmed.

  BLG-WPC (protein content 80%, Domo) 2.5 kg was dissolved in 500 L of ion exchange water to a substrate concentration of 0.5%. After adjusting to pH 8 with potassium hydroxide, add 5 g of trypsin (derived from porcine pancreas, trypsin activity 1,200 units / mg or more, chymotrypsin activity 300 units / mg or less) to 0.2% enzyme substrate ratio, 40 ° C., 6 hours, enzyme Reacted. After completion of the reaction, the mixture was heated at 120 ° C. for 3 seconds to deactivate and sterilize the enzyme activity to obtain an enzyme-degraded peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average molecular weight cut off of 5,000 to obtain a permeate. Further, the permeate was fractionated with an ultrafiltration membrane having an average molecular weight cut off of 1,000 to obtain a retentate. In the peptide composition, a peptide ([Formula 1]; Peptide 1) containing all and / or a part of the 97th to 124th sequence in the entire β-lactoglobulin 162 amino acid sequence was confirmed.

  BLG-WPC (protein content 80%, Domo) 2.5 kg was dissolved in 500 L of ion exchange water to a substrate concentration of 0.5%. After adjusting to pH 8 with potassium hydroxide, 50 g of purified trypsin (derived from porcine pancreas, trypsin activity of 4,500 USP / mg or more, chymotrypsin activity of 50 USP / mg or less) was added to an enzyme substrate ratio of 2.0% at 40 ° C. for 6 hours. Enzymatic reaction was performed. After completion of the reaction, the mixture was heated at 120 ° C. for 3 seconds to deactivate and sterilize the enzyme activity to obtain an enzyme-degraded peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average molecular weight cut off of 5,000 to obtain a permeate. Further, the permeate was fractionated with an ultrafiltration membrane having an average molecular weight cut off of 1,000 to obtain a retentate. In the peptide composition, a peptide ([Formula 1]; Peptide 1) containing all and / or a part of the 97th to 124th sequence in the entire β-lactoglobulin 162 amino acid sequence was confirmed.

  50 g of BLG-WPC (protein content 80%, Domo) was dissolved in 500 kL of ion-exchanged water to a substrate concentration of 10.0%. After adjusting to pH 8 with sodium hydroxide, 100 kg of trypsin (derived from porcine pancreas, trypsin activity of 1,200 units / mg or more, chymotrypsin activity of 300 units / mg or less) was added to an enzyme substrate ratio of 0.2% at 50 ° C. for 5 hours. Enzymatic reaction was performed. After completion of the reaction, the mixture was heated at 120 ° C. for 3 seconds to deactivate and sterilize the enzyme activity to obtain an enzyme-degraded peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average molecular weight cut off of 1,000 to obtain a permeate. In the peptide composition, a peptide ([Formula 1]; Peptide 1) containing all and / or a part of the 97th to 124th sequence in the entire β-lactoglobulin 162 amino acid sequence was confirmed.

  25 kg of BLG-WPC (protein content 80%, Domo) was dissolved in 1 kL of ion exchange water to a substrate concentration of 2.5%. After adjusting to pH 8 with potassium hydroxide, 500 g trypsin (derived from porcine pancreas, trypsin activity 1,200 units / mg or more, chymotrypsin activity 300 units / mg or less) is added to an enzyme substrate ratio of 2.0% at 40 ° C. for 6 hours. Reacted. After completion of the reaction, the mixture was heated at 120 ° C. for 3 seconds to deactivate and sterilize the enzyme activity to obtain an enzyme-degraded peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average molecular weight cut off of 5,000 to obtain a permeate, and further fractionation was performed with an ultrafiltration membrane having an average fractional molecular weight of 1,000 to obtain a retentate. In the peptide composition, a peptide ([Formula 1]; Peptide 1) containing all and / or a part of the 97th to 124th sequence in the entire β-lactoglobulin 162 amino acid sequence was confirmed.

  25 kg of BLG-WPC (protein content 80%, Domo) was dissolved in 1 kL of ion exchange water to a substrate concentration of 2.5%. After adjusting to pH 8 with sodium hydroxide, 50 g of purified trypsin (derived from porcine pancreas, trypsin activity of 4,500 USP / mg or more, chymotrypsin activity of 50 USP / mg or less) was added to an enzyme substrate ratio of 0.2% at 40 ° C. for 6 hours. Enzymatic reaction was performed. After completion of the reaction, the mixture was heated at 120 ° C. for 3 seconds to deactivate and sterilize the enzyme activity to obtain an enzyme-degraded peptide composition. Thereafter, fractionation was performed with an ultrafiltration membrane having an average molecular weight cut off of 5,000 to obtain a permeate, and further fractionation was performed with an ultrafiltration membrane having an average fractional molecular weight of 1,000 to obtain a retentate. In the peptide composition, a peptide ([Formula 1]; Peptide 1) containing all and / or a part of the 97th to 124th sequence in the entire β-lactoglobulin 162 amino acid sequence was confirmed.

[Test Example 1]
For the peptide 3 containing composition obtained in Example 1 and the peptide 4 containing composition obtained in Example 2, the T cell reactivity obtained from allergic patients was examined in order to examine the immune tolerance inducing effect. Evaluation was made by a ball stimulation test. The results are shown in FIG. 2 for interferon γ production and FIG. 3 for lymphocyte stimulation.
Both interferon gamma production and lymphocyte stimulation showed T cell reactivity similar to that of the substrate BLG, and an immune tolerance inducing effect was observed.

[Test Example 2]
About the composition containing peptide 4 obtained in Example 2 and peptide 2 of the synthetic peptide obtained in Example 1, cell proliferation was evaluated using T cell clones established from the serum of a milk allergy patient. The results are shown in FIG.
In the peptide 4 containing composition, T cell reactivity similar to that of peptide 2 was observed.

[Test Example 3]
About the peptide 3 containing composition obtained in Example 1, and the peptide 4 containing composition obtained in Example 2 and Example 3, B cell reactivity that may cause immediate allergic symptoms such as anaphylactic shock Was evaluated by the competitive Eliza method. The results are shown in FIGS.
The B cell reactivity was attenuated in both compositions containing peptide 3 and peptide 4 as compared to the substrate BLG before the degradation reaction.

  From the above results, the peptide ([Formula 2]; Peptide 3) -containing composition obtained in Example 1 and the peptide ([Formula 3]; Peptide 4) -containing composition obtained in Examples 2 and 3 were used. It has been clarified that all have excellent properties of inducing oral immune tolerance to humans by maintaining T cell reactivity and decreasing B cell reactivity. The amino acid sequence corresponding to positions 97-124 of the BLG amino acid sequence (Thr-Asp-Tyr-Lys-Lys-Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro -Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu-Val-Arg [Formula 1]; Peptide compositions containing all and / or part of peptide 1) also have T cell reactivity It has been shown that it has excellent properties of inducing oral tolerance to humans by maintaining and attenuating B cell reactivity.

It is the figure which evaluated the cell proliferation property of the T cell with the synthetic peptide (peptide 2) of the amino acid sequence corresponding to the 97-117th amino acid sequence of BLG using the T cell clone established from the serum of the milk allergy patient. Example 1). It is the figure which evaluated the T cell reactivity obtained from the milk allergy patient about the peptide 3 containing composition and the peptide 4 containing composition by the amount of interferon-gamma production (Example 1, Example 2; Test example 1). It is the figure which evaluated the T cell reactivity obtained from the milk allergy patient about the peptide 3 containing composition and the peptide 4 containing composition in the lymphocyte stimulation test (Example 1, Example 2; Test example 1). It is the figure which evaluated the cell proliferation property using the T cell clone established from the serum of a milk allergy patient about the composition containing peptide 4 and a synthetic peptide (peptide 2) (Example 1, Example 2; Test example 2). . It is the figure which evaluated B cell reactivity which may cause an immediate type | mold allergic symptom, such as an anaphylactic shock, by the competitive ELISA method about the composition containing peptide 3 (Example 1; Test example 3). It is the figure which evaluated B cell reactivity which may cause an immediate type | mold allergy symptom, such as an anaphylactic shock, by the competitive ELISA method about the composition containing peptide 4 (Example 2, Example 3; Test example 3).

Claims (6)

A peptide composition having the ability to induce oral tolerance, comprising as an active ingredient a peptide comprising all and / or part of the amino acid sequence represented by the following [Formula 1].
Thr-Asp-Tyr-Lys-Lys-Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys- Leu-Val-Arg [Formula 1] A peptide composition having the ability to induce oral tolerance, comprising a peptide containing all and / or a part of the amino acid sequence represented by the following [Formula 2] as an active ingredient.
Tyr-Leu-Leu-Phe-Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu-Val-Arg [Formula 2] A peptide composition having the ability to induce oral tolerance, comprising a peptide containing all and / or part of the amino acid sequence represented by the following [Formula 3] as an active ingredient.
Cys-Met-Glu-Asn-Ser-Ala-Glu-Pro-Glu-Gln-Ser-Leu-Val-Cys-Gln-Cys-Leu [Formula 3]   An oral tolerance inducer comprising the peptide composition according to any one of claims 1 to 3 as an active ingredient.   A method for producing a peptide composition having an ability to induce oral tolerance, characterized in that β-lactoglobulin is decomposed with a proteolytic enzyme, treated with an ultrafiltration membrane having a molecular weight of 5,000, and obtained as a permeate.   A method for producing a peptide composition having an ability to induce oral tolerance, wherein the peptide composition according to claim 5 is treated with an ultrafiltration membrane having a molecular weight of 1,000 to obtain a residue thereof.

Images